Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEpe Special Opp Regulatory News (ESO)

Share Price Information for Epe Special Opp (ESO)

Share Price is delayed by 15 minutes
Get Live Data
232.00    -3.00 (-1.28%)
Bid:
226.00
Ask:
238.00
Spread: 12.00 (5.31%)
Market Cap: £56.71m
ESO Live PriceLast checked at - London Stock Exchange

Intraday Epe Special Opp Share Chart

Portfolio Update

29 Mar 2018 07:00

RNS Number : 3283J
EPE Special Opportunities PLC
29 March 2018
 

EPE Special Opportunities plc

29 March 2018

 

This announcement contains inside information

 

EPE Special Opportunities plcPortfolio Update

EPE Special Opportunities plc ("ESO plc", or the "Company") announces that Pharmacy2U Limited ("P2U"), a company in which it has a minority investment via ESO Investments 1 LP ("ESO 1 LP"), has raised a further £40 million of new growth capital to support the rapid expansion of its online NHS repeat prescription service.

P2U is England's leading online NHS pharmacy and is the fastest growing pharmacy group in the country, with 25,000 new patient registrations in the last month alone and year-on-year growth in patient numbers of 178%.

As well as offering consumers increased choice and convenience, P2U's online prescription management service is highly beneficial for the healthcare economy, saving GPs an estimated six hours and 40 minutes a week on paperwork. It is estimated that managing repeat prescriptions online could save the NHS over £300 million per year on prescription costs.

The growth capital raise was led by G Square Capital, a European private equity firm focussed on the healthcare sector. In conjunction with the new investment, G Square Capital also acquired a majority of the share capital of P2U from existing shareholders and as a result is now the majority shareholder.

The new investment will allow P2U to invest further in technology infrastructure to support customer demand and remain at the forefront of innovation in digital pharmacy services. P2U's state-of-the-art, award winning dispensing facility in Leeds is already the largest and most technologically advanced in the United Kingdom, with the ability to dispense one million prescription items per month.

ESO 1 LP has realised 50% of its existing investment in P2U in the transaction, implying a 2.0x Money Multiple realised return. The transaction was completed at a premium to the holding value of P2U. The remaining 50% of ESO 1 LP's investment has been retained to benefit from the growth potential in P2U offered by the £40 million investment. This retained investment offers further upside in terms of Money Multiple returns to ESO 1 LP

The person responsible for releasing this information on behalf of the Company is Hilary Jones of R&H Fund Services (Jersey) Limited.

 

Enquiries:

 

EPIC Private Equity LLP

+44 (0) 207 269 8865

Alex Leslie

R&H Fund Services (Jersey) Limited

+44 (0) 1534 825 323

Hilary Jones

Cardew Group Limited

+44 (0) 207 930 0777

Richard Spiegelberg

Numis Securities Limited

+44 (0) 207 260 1000

Nominated Advisor:

Stuart Skinner / Hugh Jonathan

Corporate Broker:

Charles Farquhar

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PFUDBGDXXBDBGII
Date   Source Headline
10th Nov 20227:00 amRNSNet Asset Value(s)
26th Oct 20227:00 amRNSTransaction in Own Shares
12th Oct 20227:00 amRNSNet Asset Value(s)
7th Oct 20228:00 amRNSInvestment
30th Sep 20226:29 pmRNSTransaction in Own Shares
30th Sep 20226:28 pmRNSHolding(s) in Company
30th Sep 20228:00 amRNSAnnouncement of Buy Backs & Prospective Investment
16th Sep 20227:00 amRNSHolding(s) in Company
9th Sep 20227:00 amRNSNet Asset Value(s)
6th Sep 20227:00 amRNSInterim Report
1st Aug 20227:00 amRNSInterest Payment on Unsecured Loan Notes
22nd Jul 20225:30 pmRNSPosting of Annual Report and Accounts
21st Jul 20227:00 amRNSAmendment and Extension of Unsecured Loan Notes
12th Jul 20227:00 amRNSNet Asset Value(s)
5th Jul 20227:01 amRNSVesting - Share Matching Scheme/PDMR Shareholdings
5th Jul 20227:00 amRNSHolding(s) in Company
17th Jun 20225:00 pmRNSResult of AGM
10th Jun 20227:00 amRNSNet Asset Value(s)
16th May 20225:30 pmRNSNotice of AGM
12th May 20227:00 amRNSNet Asset Value(s)
14th Apr 20227:00 amRNSNet Asset Value(s)
8th Apr 20225:10 pmRNSHolding(s) in Company
8th Apr 20224:32 pmRNSHolding(s) in Company
8th Apr 20224:30 pmRNSVesting - Share Matching Scheme/PDMR Shareholdings
22nd Mar 20227:00 amRNSAnnual Financial Report
18th Feb 20225:00 pmRNSDirector/PDMR Shareholding
10th Feb 20224:16 pmRNSDirector/PDMR Shareholding
10th Feb 20224:15 pmRNSHolding(s) in Company
7th Feb 20227:00 amRNSTrading Statement
1st Feb 20227:00 amRNSInterest Payment on Unsecured Loan Notes
14th Jan 20227:00 amRNSNet Asset Value(s)
5th Jan 20227:00 amRNSUpdate on Share Buy Backs
24th Dec 20217:00 amRNSTransaction in Own Shares
23rd Dec 20218:36 amRNSTransaction in Own Shares
22nd Dec 20217:00 amRNSTransaction in Own Shares
21st Dec 20217:00 amRNSTransaction in Own Shares
20th Dec 20217:00 amRNSTransaction in Own Shares
16th Dec 20217:00 amRNSTransaction in Own Shares
15th Dec 20217:00 amRNSResult of ZDP Share Placing
13th Dec 20216:23 pmRNSResult of EGM
13th Dec 20217:00 amRNSTransaction in Own Shares
10th Dec 20217:00 amRNSTransaction in Own Shares
9th Dec 20217:00 amRNSNet Asset Value and Commencement of Share Buybacks
2nd Dec 20214:41 pmRNSPublication of ZDP Prospectus
2nd Dec 20217:15 amRNSInvestment
19th Nov 20217:00 amRNSNotice of Extraordinary General Meeting
8th Nov 20217:00 amRNSNet Asset Value(s)
15th Oct 20217:00 amRNSDirector/PDMR Shareholding
8th Oct 20217:00 amRNSNet Asset Value(s)
7th Sep 20217:00 amRNSInterim Review and Unaudited Financial Statements

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.